CDH17在肿瘤中的作用研究进展
Relationship between CDH17 and Tumor Progression
DOI: 10.12677/WJCR.2021.114018, PDF,    国家自然科学基金支持
作者: 姜一帆, 张月英*：山东第一医科大学基础医学院病理学与病理生理学研究室，山东 济南；山东第一医科大学第一附属医院基础医学研究所，山东 济南
关键词: CDH17；肿瘤；CDH17； Tumor
摘要: 肿瘤的发生发展是一个多因素、多步骤相互作用的过程，其中细胞间的粘附及运动能力的失调是肿瘤发生发展的重要机制之一。CDH17是近年来发现的钙粘连蛋白家族中的新成员，在多种肿瘤的侵袭及转移中发挥重要作用。本文就CDH17在多种常见肿瘤中的作用研究进展进行综述。
Abstract: The occurrence and development of tumor is a multi-factor and multi-step process, in which cell adhesion is one of the important mechanisms. Dysregulation of cadherin-mediated cell adhesion is thought to play a major role during tumor proliferation and cell invasion. CDH17 is a new member of the cadherin family discovered in recent years, and it plays an important role in tumor invasion and metastasis. In this review, we aim to explore the relationship between cadherin adhesion molecule CDH17 and tumor progression.
文章引用：姜一帆, 张月英. CDH17在肿瘤中的作用研究进展[J]. 世界肿瘤研究, 2021, 11(4): 131-136. https://doi.org/10.12677/WJCR.2021.114018

参考文献

[1] Berndorff, D., Gessner, R., Kreft, B., Schnoy, N., Lajous-Petter, A.M., Loch, N., Reutter, W., Hortsch, M. and Tauber, R. (1994) Liver-Intestine Cadherin: Molecular Cloning and Characterization of a Novel Ca2+-Dependent Cell Adhesion Molecule Expressed in Liver and Intestine. Journal of Cell Biology, 125, 1353-1369.
[Google Scholar] [CrossRef] [PubMed]
[2] Gul, I.S., Hulpiau, P., Saeys, Y. and van Roy, F. (2017) Evolution and Diversity of Cadherins and Catenins. Experimental Cell Research, 358, 3-9.
[Google Scholar] [CrossRef] [PubMed]
[3] 潘地铃. CDH17在肿瘤发生发展中的作用[J]. 中国医疗前沿, 2012, 7(8): 10-11.
[4] Kreft, B., Berndorff, D., Böttinger, A., Finnemann, S., Wedlich, D., Hortsch, M., Tauber, R. and Gessner, R. (1997) LI-Cadherin-Mediated Cell-Cell Adhesion Does Not Require Cytoplasmic Interactions. Journal of Cell Biology, 136, 1109-1121.
[Google Scholar] [CrossRef] [PubMed]
[5] Nollet, F., Kools, P. and van Roy, F. (2000) Phylogenetic Analysis of the Cadherin Super Family Allow Sidentification of Six Major Subfamilies Besides Several Solitary Members. Journal of Molecular Biology, 299, 551-572.
[Google Scholar] [CrossRef] [PubMed]
[6] Marshall, J.F. (2018) Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor? Clinical Cancer Research, 24, 253-255.
[Google Scholar] [CrossRef] 
[7] Lee, H.J., Nam, K.T., Park, H.S., Kim, M.A., Lafleur, B.J., Aburatani, H., Yang, H.K., Kim, W.H. and Goldenring, J.R. (2010) Gene Expression Profiling of Metaplastic Lineages Identifies CDH17 as a Prognostic Marker in Early Stage Gastric Cancer. Gastroenterology, 139, 213-25.e3.
[Google Scholar] [CrossRef] [PubMed]
[8] 左婷婷, 郑荣寿, 曾红梅, 张思维, 陈万青. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1): 52-58
[9] Becker, K.F., Atkinson, M.J., Reich, U., Huang, H.-H., Nekarda, H., Siewert, J.R., et al. (1993) Exon Skipping in the E-Cadherin Gene Transcript in Metastatic Human Gastric Carcinomas. Human Molecular Genetics, 2, 803-804.
[Google Scholar] [CrossRef] [PubMed]
[10] Ito, R., Oue, N., Yoshida, K., Kunimitsu, K., Nakayama, H., Nakachi, K. and Yasui, W. (2005) Clinicopathological Significant and Prognostic Influence of Cadherin-17 Expression in Gastric Cancer. Virchows Archiv, 447, 717-722.
[Google Scholar] [CrossRef] [PubMed]
[11] Wong, B.W., Luk, J.M., Ng, I.O., Hu, M.Y., Liu, K.D. and Fan, S.T. (2003) Identification of Liver-Intestine Cadherin in Hepatocellular Carcinoma—A Potential Disease Marker. Biochemical and Biophysical Research Communications, 311, 618-624.
[Google Scholar] [CrossRef] [PubMed]
[12] Long, Z.W., Zhou, M.L., Fu, J.W., Chu, X.Q. and Wang, Y.N. (2015) Association between Cadherin-17 Expression and Pathological Characteristics of Gastric Cancer: A Meta-Analysis. World Journal of Gastroenterology, 21, 3694- 3705.
[Google Scholar] [CrossRef] [PubMed]
[13] Park, S.S., Kang, S.H., Park, J.M., Kim, J.H., Oh, S.C., Lee, J.H., Chae, Y.S., Kim, S.J., Kim, C.S. and Mok, Y.J. (2007) Expression of Liver-Intestine Cadherin and Its Correlation with Lymph Node Metastasis in Gastric Cancer: Can It Predict N Stage Preoperatively? Annals of Surgical Oncology, 14, 94-99.
[Google Scholar] [CrossRef] [PubMed]
[14] Li, R., Yang, H.Q., Xi, H.L., Feng, S. and Qin, R.H. (2017) Inhibition of CDH17 Gene Expression via RNA Interference Reduces Proliferation and Apoptosis of Human MKN28 Gastric Cancer Cells. International Journal of Oncology, 50, 15-22.
[Google Scholar] [CrossRef] [PubMed]
[15] Liu, L.X., Lee, N.P., Chan, V.W., Xue, W., Zender, L., Zhang, C., Mao, M., Dai, H., Wang, X.L., Xu, M.Z., Lee, T.K., Ng, I.O., Chen, Y., Kung, H.F., Lowe, S.W., Poon, R.T., Wang, J.H. and Luk, J.M. (2009) Targeting Cadherin-17 Inactivates Wnt Signaling and Inhibits Tumor Growth in Liver Carcinoma. Hepatology, 50, 1453-1463. Erratum in: Hepatology, 2010, 51, 358.
[Google Scholar] [CrossRef] [PubMed]
[16] Qu, L.P., Zhong, Y.M., Zheng, Z. and Zhao, R.X. (2017) CDH17 Is a Downstream Effector of HOXA13 in Modulating the Wnt/β-Catenin Signaling Pathway in Gastric Cancer. European Review for Medical and Pharmacological Sciences, 21, 1234-1241.
[17] Llovet, J.M., Burroughs, A. and Bruix, J. (2003) Hepatocellular Carcinoma. Lancet, 362, 1907-1917.
[Google Scholar] [CrossRef] 
[18] Lee, N.P., Poon, R.T., Shek, F.H., Ng, I.O. and Luk, J.M. (2010) Role of Cadherin-17 in Oncogenesis and Potential Therapeutic Implications in Hepatocellular Carcinoma. Biochimica et Biophysica Acta, 1806, 138-145.
[Google Scholar] [CrossRef] [PubMed]
[19] Wang, X.Q., Luk, J.M., Leung, P.P., Wong, B.W., Stanbridge, E.J. and Fan, S.T. (2005) Alternative mRNA Splicing of Liver Intestine-Cadherin in Hepatocellular Carcinoma. Clinical Cancer Research, 11, 483-489.
[20] Wang, Y., Shek, F.H., Wong, K.F., Liu, L.X., Zhang, X.Q., Yuan, Y., Khin, E., Hu, M.Y., Wang, J.H., Poon, R.T., Hong, W., Lee, N.P. and Luk, J.M. (2013) Anti-Cadherin-17 Antibody Modulates Beta-Catenin Signaling and Tumorigenicity of Hepatocellular Carcinoma. PLoS ONE, 8, e72386.
[Google Scholar] [CrossRef] [PubMed]
[21] Qiu, H.B., Zhang, L.Y., Ren, C., Zeng, Z.L., Wu, W.J., Luo, H.Y., Zhou, Z.W. and Xu, R.H. (2019) Correction: Targeting CDH17 Suppresses Tumor Progression in Gastric Cancer by Downregulating Wnt/β-Catenin Signaling. PLoS ONE, 14, Article ID: e0217124. Erratum for: PLoS ONE, 2013, 8, Article ID: e56959.
[Google Scholar] [CrossRef] [PubMed]
[22] Han, Z., Huang, X.D., Liu, M., Tan, J., Zhu, Q.X., Wang, Y.F., Cai, Y.S., Chen, A.F. and Tian, X. (2017) Knock-Down of Cadherin 17 Inhibits Proliferation and Promote Apoptosis in Noscapine-Resistant Human SW480 Colon Cancer Cells. Chinese Journal of Cellular and Molecular Immunology, 33, 606-610.
[23] Kwak, J.M., Min, B.W., Lee, J.H., Choi, J.S., Lee, S.I., Park, S.S., Kim, J., Um, J.W., Kim, S.H. and Moon, H.Y. (2007) The Prognostic Significance of E-Cadherin and Liver Intestine-Cadherin Expression in Colorectal Cancer. Diseases of the Colon & Rectum, 50, 1873-1880.
[Google Scholar] [CrossRef] [PubMed]
[24] Ratto, C., Sofo, L., Ippoliti, M., Merico, M., Doglietto, G.B and Crucitti, F. (1998) Prognostic Factors in Colorectal Cancer. Literature Review for Clinical Application. Diseases of the Colon & Rectum, 41, 1033-1049.
[Google Scholar] [CrossRef] 
[25] Takamura, M., Ichida, T., Matsuda, Y., Kobayashi, M., Yamagiwa, S., Genda, T., Shioji, K., Hashimoto, S., Nomoto, M., Hatakeyama, K., Ajioka, Y., Sakamoto, M., Hirohashi, S. and Aoyagi, Y. (2004) Reduced Expression of Liver-Intes- tine Cadherin Is Associated with Progression and Lymph Node Metastasis of Human Colorectal Carcinoma. Cancer Letters, 212, 253-259.
[Google Scholar] [CrossRef] [PubMed]
[26] Ivanov, D.B., Philippova, M.P. and Tkachuk, V.A. (2001) Structure and Functions of Classical Cadherins. Biochemistry (Moscow), 66, 1174-1186.
[Google Scholar] [CrossRef] 
[27] Takamura, M., Sakamoto, M., Ino, Y., Shimamura, T., Ichida, T., Asakura, H. and Hirohashi, S. (2003) Expression of Liver-Intestine Cadherin and Its Possible Interaction with Galectin-3 in Ductal Adenocarcinoma of the Pancreas. Cancer Science, 94, 425-430.
[Google Scholar] [CrossRef] [PubMed]
[28] Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C.D., Biankin, A.V., Neale, R.E., Tempero, M., Tuveson, D.A., Hruban, R.H. and Neoptolemos, J.P. (2016) Pancreatic Cancer. Nature Reviews Disease Primers, 2, Article No. 16022.
[Google Scholar] [CrossRef] [PubMed]
[29] Liu, X., Huang, Y., Yuan, H., Qi, X., Manjunath, Y., Avella, D., Kaifi, J.T., Miao, Y., Li, M., Jiang, K. and Li, G. (2019) Disruption of Oncogenic Liver-Intestine Cadherin (CDH17) Drives Apoptotic Pancreatic Cancer Death. Cancer Letters, 454, 204-214.
[Google Scholar] [CrossRef] [PubMed]
[30] Bhanvadia, S.K. (2018) Bladder Cancer Survivorship. Current Urology Reports, 19, Article No. 111.
[Google Scholar] [CrossRef] [PubMed]
[31] Rao, Q., Williamson, S.R., Lopez-Beltran, A., Montironi, R., Huang, W., Eble, J.N., Grignon, D.J., Koch, M.O., Idrees, M.T., Emerson, R.E., Zhou, X.J., Zhang, S., Baldridge, L.A. and Cheng, L. (2013) Distinguishing Primary Adenocarcinoma of the Urinary Bladder from Secondary Involvement by Colorectal Adenocarcinoma: Extended Immunohistochemical Profiles Emphasizing Novel Markers. Modern Pathology, 26, 725-732.
[Google Scholar] [CrossRef] [PubMed]

为你推荐